The impact of antiviral therapy on the course of chronic HCV infection: A systematic review

2003 ◽  
Vol 38 ◽  
pp. 123 ◽  
Author(s):  
P.L. Almasio ◽  
G. Venezia ◽  
A. Craxi
Keyword(s):  
Systematic Review ◽  
Antiviral Therapy ◽  
Hcv Infection ◽  
Chronic Hcv Infection ◽  
Chronic Hcv ◽  
The Impact

scholarly journals French hepatitis C care cascade: substantial impact of direct-acting antivirals, but the road to elimination is still long

2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Cécile Brouard ◽  
Josiane Pillonel ◽  
Marjorie Boussac ◽  
Victor de Lédinghen ◽  
Antoine Rachas ◽  
...  
Keyword(s):  
Hepatitis C ◽  
Antiviral Treatment ◽  
Hcv Infection ◽  
World Health ◽  
Direct Acting Antivirals ◽  
Substantial Impact ◽  
Chronic Hcv Infection ◽  
Chronic Hcv ◽  
Direct Acting ◽  
The Impact

Abstract Background Hepatitis C virus (HCV) elimination by 2030, as targeted by the World Health Organization (WHO), requires that 90% of people with chronic infection be diagnosed and 80% treated. We estimated the cascade of care (CoC) for chronic HCV infection in mainland France in 2011 and 2016, before and after the introduction of direct-acting antivirals (DAAs). Methods The numbers of people (1) with chronic HCV infection, (2) aware of their infection, (3) receiving care for HCV and (4) on antiviral treatment, were estimated for 2011 and 2016. Estimates for 1) and 2) were based on modelling studies for 2011 and on a virological sub-study nested in a national cross-sectional survey among the general population for 2016. Estimates for 3) and 4) were made using the National Health Data System. Results Between 2011 and 2016, the number of people with chronic HCV infection decreased by 31%, from 192,700 (95% Credibility interval: 150,900-246,100) to 133,500 (95% Confidence interval: 56,900-312,600). The proportion of people aware of their infection rose from 57.7 to 80.6%. The number of people receiving care for HCV increased by 22.5% (representing 25.7% of those infected in 2016), while the number of people on treatment increased by 24.6% (representing 12.1% of those infected in 2016). Conclusions This study suggests that DAAs substantially impact CoC. However, access to care and treatment for infected people remained insufficient in 2016. Updating CoC estimates will help to assess the impact of new measures implemented since 2016 as part of the goal to eliminate HCV.

P734 A SYSTEMATIC REVIEW OF INTERVENTIONS TO REDUCE ALCOHOL CONSUMPTION AMONG INDIVIDUALS WITH CHRONIC HCV INFECTION

2014 ◽  
Vol 60 (1) ◽  
pp. S314-S315 ◽  
Author(s):  
J.S. Doyle ◽  
D. Hunt ◽  
E.J. Aspinall ◽  
S.J. Hutchinson ◽  
D.J. Goldberg ◽  
...  
Keyword(s):  
Systematic Review ◽  
Alcohol Consumption ◽  
Hcv Infection ◽  
Reduce Alcohol Consumption ◽  
Chronic Hcv Infection ◽  
Chronic Hcv

Clinical responders to antiviral therapy of chronic HCV infection show elevated antiviral CD4+ and CD8+ T-cell responses

2007 ◽  
Vol 14 (5) ◽  
pp. 318-329 ◽  
Author(s):  
Vinodh Pillai ◽  
William M. Lee ◽  
Dwain L. Thiele ◽  
Nitin J. Karandikar
Keyword(s):  
T Cell ◽  
Antiviral Therapy ◽  
T Cell Responses ◽  
Cd8 T Cell ◽  
Hcv Infection ◽  
Cell Responses ◽  
Chronic Hcv Infection ◽  
Chronic Hcv

Direct-Acting Antiviral Therapy for Chronic HCV Infection Results in Liver Stiffness Regression Over 12 Months Post-treatment

2017 ◽  
Vol 63 (2) ◽  
pp. 486-492 ◽  
Author(s):  
Justin Chan ◽  
Neliswa Gogela ◽  
Hui Zheng ◽  
Sara Lammert ◽  
Tokunbo Ajayi ◽  
...  
Keyword(s):  
Antiviral Therapy ◽  
Liver Stiffness ◽  
Post Treatment ◽  
Hcv Infection ◽  
Direct Acting Antiviral ◽  
Chronic Hcv Infection ◽  
Chronic Hcv ◽  
Direct Acting

Antiviral therapy of chronic HCV infection in kidney transplant recipient

2019 ◽  
Vol 21 (2) ◽  
pp. 191-198
Author(s):  
M.L. Zubkin ◽  
◽  
I.G. Kim ◽  
O.S. Arisheva ◽  
N.A. Tomilina ◽  
...  
Keyword(s):  
Transplant Recipient ◽  
Antiviral Therapy ◽  
Kidney Transplant ◽  
Kidney Transplant Recipient ◽  
Hcv Infection ◽  
Chronic Hcv Infection ◽  
Chronic Hcv

Association of chronic hepatitis C virus infection with an increased risk of lung cancer: A systematic review and meta-analysis.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e13562-e13562
Author(s):  
Ben Ponvilawan ◽  
Nipith Charoenngam ◽  
Pongprueth Rujirachun ◽  
Phuuwadith Wattanachayakul ◽  
Surapa Tornsatitkul ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Systematic Review ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Search Strategy ◽  
Meta Analysis ◽  
Hcv Infection ◽  
Increased Risk ◽  
Chronic Hcv Infection ◽  
Chronic Hcv

e13562 Background: Chronic hepatitis C virus (HCV) infection is associated with increased risk of multiple types of extrahepatic cancer, such as lymphomas, thyroid cancer and renal cancer. However, whether HCV infection also increases the risk of lung cancer is still inconclusive. This systematic review and meta-analysis was performed in order to determine the relationship between chronic HCV infection and lung cancer. Methods: A systematic review was performed using EMBASE and MEDLINE databases from inception to November 2019 with search strategy that represents “hepatitis C virus” and “cancer”. Eligible studies must be cohort studies which include patients with chronic HCV infection and comparators without HCV infection, then follow them for incident lung cancer. Relative risk, incidence rate ratio (IRR), standardized incidence ratio, or hazard risk ratio of this association along with associated 95% confidence interval (CI) from each study were extracted and combined for the calculation of the pooled effect estimate using the random effect, generic inverse variance. Results: 20,459 articles were discovered using the aforementioned search strategy. After two rounds of review, eight studies fulfilled the inclusion criteria and were included into the meta-analysis. Chronic HCV infection was significantly associated with increased risk of lung cancer with the pooled relative risk of 1.94 (95% CI, 1.56 – 2.42; I2 = 87%). Funnel plot was fairly symmetric and not suggestive of presence of publication bias. Conclusions: Chronic HCV infection is significantly associated with a 1.94-fold increased risk in the development of lung cancer compared to no infection.

scholarly journals Hepatocellular carcinoma after direct-acting antiviral therapy for chronic HCV infection: Is it a real risk?

IDCases ◽  
2018 ◽  
Vol 14 ◽  
pp. e00450 ◽  
Author(s):  
Cátia Dias ◽  
Filipa Duarte-Ribeiro ◽  
Sara Pipa ◽  
Ana Rita Barbosa ◽  
Margarida Mota ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Antiviral Therapy ◽  
Hcv Infection ◽  
Direct Acting Antiviral ◽  
Real Risk ◽  
Chronic Hcv Infection ◽  
Chronic Hcv ◽  
Direct Acting

Real-world medical costs of antiviral therapy among patients with chronic HCV infection and advanced hepatic fibrosis

2016 ◽  
Vol 31 (11) ◽  
pp. 1851-1859 ◽  
Author(s):  
Raoel Maan ◽  
Remziye Zaim ◽  
Adriaan J van der Meer ◽  
Jordan J Feld ◽  
Heiner Wedemeyer ◽  
...  
Keyword(s):  
Antiviral Therapy ◽  
Hepatic Fibrosis ◽  
Real World ◽  
Medical Costs ◽  
Hcv Infection ◽  
Chronic Hcv Infection ◽  
Chronic Hcv

scholarly journals Management of Multiple Myeloma Complicated by Hepatitis C Virus Reactivation: The Role of New Antiviral Therapy

2015 ◽  
Vol 3 (1) ◽  
Author(s):  
Parag Mahale ◽  
Sheeba K. Thomas ◽  
Andreas Kyvernitakis ◽  
Harrys A. Torres
Keyword(s):  
Multiple Myeloma ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Antiviral Therapy ◽  
Hcv Infection ◽  
Virus Reactivation ◽  
First Case ◽  
Life Saving ◽  
Chronic Hcv Infection ◽  
Chronic Hcv

Abstract Reactivation of chronic hepatitis C virus (HCV) infection has been reported in cancer patients receiving chemotherapy. In this study, we report the first case, to our knowledge, of thalidomide-induced acute exacerbation and reactivation of chronic HCV infection complicating management of multiple myeloma. Sofosbuvir-based antiviral therapy helped achieve viral clearance and normalization of liver enzymes, thus allowing access to future potentially life-saving chemotherapy agents.

Sign in / Sign up

Export Citation Format

Share Document